In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites
Academic source · Nature Materials
Source published: · Event / reporting date: 2026-11-06
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What the paper reports
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
Why this paper is included
Analysis: Combining carrier activity with RNA-mediated cell engineering may create differentiated delivery strategies, requiring careful mechanistic, distribution, and safety assessment.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections
mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTAC